🎙️ Melinda Knows Best at the AAD! 🌟
We’ve got a special LATEBREAKER episode for you, continuing our coverage from the American Academy of Dermatology in San Diego!
👟💡 Pro Tip: Don't miss Dr. Gooderham’s advice on navigating massive convention centers in style and comfort!
We dive into the highly anticipated Delta 3 study, shedding light on long-term safety and efficacy of Delgocitinib cream for Chronic Hand Eczema.
- Subjects who completed the 16-week treatment period in one of the parent trials DELTA 1 and DELTA 2 were treated with twice daily delgocitinib cream as needed to control their chronic hand eczema for 36 weeks.
Practical Tips for Dermatology Practices 🏥💼
- Adapting treatment plans for chronic hand eczema.
- Benefits of as-needed treatment approaches for better patient outcomes.
Dr. Gooderham’s Conference Adventures 🛫👩⚕️👨⚕️
- Dr. Gooderham also shares her intriguing encounters from Toronto to San Diego, including a surprise meeting with April Armstrong and an old friend from med school. 🛫
Episode Learning Objectives:
- Understand the primary and secondary endpoints of the Delta 3 study and its implications for treating chronic hand eczema.
- Learn about the safety profile of Delgocitinib cream and its significance in long-term treatment plans.
- Gain insights into real-world application of delgocitinib and patient adherence strategies for topical treatments
Lace up those sneakers, grab a protein bar, and join us for a walk through the latest dermatological advancements! 🥾🍫
🎙️ Melinda Knows Best at the AAD – where expert insights meet real-world application (pun intended)📍📍
Episode supported by an IME Grant from LEO Pharma
ABOUT Dr.Melinda Gooderham, MD, FRCPC ( Dermatology)
Dermatologist | Toronto
Toronto, ON
Melinda Gooderham MD MSc FRCPC Dr. Gooderham is a Dermatologist and Medical Director at the SKiN Centre for Dermatology and an Investigator with Probity Medical Research. She is an Assistant Professor at Queens University and a Consultant Physician at the Peterborough Regional Health Centre. She is a fellow of the Royal College of Physicians and Surgeons of Canada.
Dr. Gooderham has been the principal investigator for over 200 clinical trials and she practices with a focus on inflammatory diseases of the skin. She also contributes to several peer-reviewed dermatology publications as an associate editor, reviewer, and has been an author of 205 articles. She enjoys lecturing to global audiences on new therapies for skin diseases.
References
- Gooderham M. Long-term safety and efficacy of delgocitinib cream for up to 36 weeks in adults with chronic hand eczema: results of the phase 3 open-label extension DELTA 3 trial. Presented at: 2024 American Academy of Dermatology Annual Meeting; March 8-12, 2024; San Diego, CA.
📻www.skinandjoints.ca
✉️info@skinandjoints.ca